Working… Menu

Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01337752
Recruitment Status : Completed
First Posted : April 19, 2011
Last Update Posted : December 17, 2020
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
The study will evaluate the effects of BHQ880 in patients with previously untreated multiple myeloma and renal insufficiency who are not considered candidates for bisphosphonate therapy. The primary objective of the study will be to evaluate the effect of BHQ880 in combination with bortezomib and dexamethasone, compared to placebo administered with the combination on the time to first Skeletal Related Event (SRE) on study.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Renal Insufficiency Drug: BHQ880 Drug: BHQ880 Placebo Drug: bortezomib Drug: dexamethasone Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-blind, Placebo-controlled, Randomized Phase 2 Study of BHQ880, an Anti-Dickkopf1 (DKK1) Monoclonal Antibody (mAb), in Patients With Untreated Multiple Myeloma and Renal Insufficiency
Study Start Date : January 2012
Actual Primary Completion Date : May 2013
Actual Study Completion Date : May 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma

Arm Intervention/treatment
Experimental: BHQ880 + bortezomib and dexamethasone Drug: BHQ880
Drug: bortezomib
intravenous injection

Drug: dexamethasone

Placebo Comparator: BHQ880 Placebo + bortezomib and dexamethasone Drug: BHQ880 Placebo
Intravenous infusion

Drug: bortezomib
intravenous injection

Drug: dexamethasone

Primary Outcome Measures :
  1. effect of BHQ880 compared with placebo on time to first Skeletal Related Event (SRE) in patients with untreated multiple myeloma and renal insufficiency in combination with bortezomib and dexamethasone [ Time Frame: 18-month median time to first SRE assumed for the placebo arm ]
    Time to first SRE from randomization

Secondary Outcome Measures :
  1. safety and tolerability of BHQ880 in combination with bortezomib and dexamethasone [ Time Frame: From screening through month 17 ]
    Number of patients with adverse events/serious adverse events, abnormal clinical laboratory values, and the assessment of immunogenicity

  2. Characterize the PharmacoKinetics (PK) profiles of BHQ880 and bortezomib [ Time Frame: At screening and weeks 1, 2, 4, 7, 10, 11, 13, 16, 25 and 34 ]
    Determine the pharmacokinetic parameters for BHQ880 and bortezomib (Cmax, Tmax, AUC0-tlast, t1/2, and accumulation ratio of BHQ880).

  3. Evaluate the effect of BHQ880 on bone metabolism [ Time Frame: At screening and at months 3, 6, 12, and 18 ]
    1) Change in bone mineral density, measured by dual-emission X-ray absorptiometry (DXA), from randomization to 12 and 18 months; 2) Change in bone strength, measured by quantitative computed tomography (qCT), from randomization to 3 and 6 months

  4. Determine the antimyeloma effect of BHQ880 compared to placebo when used in combination with bortezomib and dexamethasone. [ Time Frame: From the first dose of study medication through month 17 ]
    1) The overall response rate (partial response plus complete response); 2) Progression-free survival following initiation of BHQ880

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   55 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Confirmed diagnosis of multiple myeloma
  2. Life expectancy of more than 6 months in the absence of intervention
  3. Must not have received previous or be receiving current antimyeloma therapies
  4. Renal insufficiency
  5. Recovered from the effects of any prior surgery or radiotherapy

Exclusion Criteria:

  1. Prior IV bisphosphonate therapy at any time or oral bisphosphonate therapy within 4 months of study entry
  2. Paget's disease of bone or uncorrected hyperparathyroidism
  3. Impaired cardiac function
  4. Known HIV, known active hepatitis B, or known or suspected hepatitis C infection
  5. Pregnant or nursing (lactating) women,
  6. Women of child-bearing potential, UNLESS agreeable to using 2 birth control methods

Other protocol-defined inclusion/exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01337752

Layout table for location information
United States, Illinois
University Chicago Hospital Dept. of Univ of Chicago (2)
Chicago, Illinois, United States, 60637
United States, Washington
Medical Oncology Associates, PS
Spokane, Washington, United States, 99208
Novartis Investigative Site
Valencia, Comunidad Valenciana, Spain, 46026
Novartis Investigative Site
Madrid, Spain, 28006
United Kingdom
Novartis Investigative Site
Bournemouth, United Kingdom, BH7 7DW
Novartis Investigative Site
Manchester, United Kingdom, M13 9WL
Novartis Investigative Site
Oxford, United Kingdom, OX3 7LJ
Novartis Investigative Site
Southampton, United Kingdom, SO16 6YD
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
Additional Information:
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals Identifier: NCT01337752    
Other Study ID Numbers: CBHQ880A2203
2009-010875-26 ( EudraCT Number )
First Posted: April 19, 2011    Key Record Dates
Last Update Posted: December 17, 2020
Last Verified: September 2020
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
multiple myeloma
renal insufficiency
untreated multiple myeloma
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Renal Insufficiency
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Kidney Diseases
Urologic Diseases
Antibodies, Monoclonal
Anti-Inflammatory Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal